The Covid pandemic and its repercussions have changed the pharmaceutical industry and the healthcare markets. Richard Stedman, the CEO of ACG Engineering, discusses the lessons learned from the global supply chain disruptions and how innovative equipment helps pharma manufacturers overcome the challenges.
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.
In response to the urgent need for sustainable solutions in the surfactants industry, companies like Locus Ingredients are developing environmentally friendly biosurfactants.
Interview with Alban Chesneau and Nicolas Castet, Carbon Waters
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
The pharmaceutical market is undergoing a profound transformation, driven by innovation among biologics and advanced therapies (ATs). This shift is not only redefining the treatment landscape but also presenting new opportunities and challenges related to the drug development and manufacturing value chain.
Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO industry is a relatively young one. There have been significant developments over its short lifespan, and it is likely that we see even more growth in the years to come.
In its latest European Chemicals Pulse Check, Deloitte surveyed senior executives in the European chemical industry and industry associations about their views on current market challenges, trends and opportunities.
